BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Merck  Santé  S.A.S.  submitted  on  29  November  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Cyanokit,  through  the  centralised 
procedure  under  Article  3  (2)  (b)  of  Regulation  (EC)  No  726/2004,  based  on  interest  of  patients  at 
Community level. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP 
on 27 April 2006.  
The legal basis for this application refers to:  
Article 8(3) of Directive 2001/83/EC, as amended - complete and independent application 
Licensing status: 
Cyanokit has been given a Marketing Authorisation in France (1996), Hong Kong (1999) and USA 
(2006) 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:   Dr. Pierre Demolis 
Co-Rapporteur:  
Dr. Ian Hudson 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 29 November 2006.  
The procedure started on 27 December 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  20  March 
2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 16 
March 2007.  
During  the  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  27 April 2007. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 11 July 
2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  24 August 2007. 
During  the  meeting  on    17  –  20  September  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Cyanokit on 20 September 2007. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  18 
September 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 23 November 2007. 
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
